EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> BioLineRx presented overall survival data from a phase 2a trial of BL-8040 in acute myeloid leukemia. Median overall survival across all dosing levels was 9.1 months. Statement

> Idorsia detailed plans to start a pivotal trial of clazosentan in patients who have suffered subarachnoid hemorrhages. Release 

> Microbiotica has teamed up with the University of Adelaide to develop a defined bacterial product for ulcerative colitis. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> GammaDelta Therapeutics appointed Michael Koslowski, M.D., as CMO. Koslowski is the former CMO of Mission Therapeutics. Release   

> NeuroVive outlicensed a treatment for Leber's hereditary optic neuropathy to BridgeBio Pharma’s new subsidiary. The deal is worth up to $60 million to NeuroVive. Statement

> Compugen raised $21 million in a registered direct offering. Release

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.